West Oak Capital’s Teva Pharmaceuticals TEVA Stock Holding History

West Oak Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,525	Closed	-$55.3K	–	386
2016 Q4	$55.3K	Hold	1,525	–	–	0.04%	174
2016 Q3	$70.2K	Hold	1,525	–	–	0.05%	157
2016 Q2	$76.6K	Hold	1,525	–	–	0.06%	143
2016 Q1	$81.6K	Hold	1,525	–	–	0.06%	132
2015 Q4	$100K	Hold	1,525	–	–	0.08%	125
2015 Q3	$86.1K	Hold	1,525	–	–	0.07%	133
2015 Q2	$90.1K	Sell	1,525 -25	-2%	-$1.54K	0.07%	130
2015 Q1	$96.6K	Hold	1,550	–	–	0.07%	127
2014 Q4	$89.1K	Hold	1,550	–	–	0.06%	127
2014 Q3	$83.3K	Hold	1,550	–	–	0.06%	128
2014 Q2	$81.3K	Sell	1,550 -200	-11%	-$10.2K	0.06%	129
2014 Q1	$92.5K	Sell	1,750 -1,375	-44%	-$63.5K	0.07%	124
2013 Q4	$125K	Sell	3,125 -2,540	-45%	-$100K	0.09%	111
2013 Q3	$214K	Sell	5,665 -50	-0.9%	-$1.95K	0.17%	97
2013 Q2	$224K	Buy	+5,715	New	+$223K	0.19%	87

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

West Oak Capital's TEVA Position: Q1 2017 in Review

West Oak Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 1,525 shares — an estimated $55.3K sold.

West Oak Capital first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $224K in Q2 2013. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

West Oak Capital reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
West Oak Capital sold 1,525 Teva Pharmaceuticals shares in Q1 2017, an estimated $55.3K.
West Oak Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
West Oak Capital's Teva Pharmaceuticals position peaked at $224K in Q2 2013.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on West Oak Capital's 13F filing for Q1 2017, filed 6 Apr 2017.